Abstract:PARP-1 (Poly (ADP-ribose) polymerase 1) is a nuclear enzyme and plays a key role in many cellular functions, such as DNA repair, modulation of chromatin structure, and recombination. Developing the PARP-1 inhibitors has emerged as an effective therapeutic strategy for a growing list of cancers. The catalytic structural domain (CAT) of PARP-1 upon binding the inhibitor allosterically regulates the conformational changes of helix domain (HD), affecting its identification with the damaged DNA. The typical type I (EB47) and III (veliparib) inhibitors were able to lengthening or shortening the retention time of this enzyme on DNA damage and thus regulating the cytotoxicity. Nonetheless, the basis underlying allosteric inhibition is unclear, which limits the development of novel PARP-1 inhibitors. Here, to investigate the distinct allosteric changes of EB47 and veliparib against PARP-1 CAT, each complex was simulated via classical and Gaussian accelerated molecular dynamics (cMD and GaMD). To study the reverse allosteric basis and mutation effects, the complexes PARP-1 with UKTT15 and PARP-1 D766/770A mutant with EB47 were also simulated. Importantly, the markov state models were built to identify the transition pathways of crucial substates of allosteric communication and the induction basis of PARP-1 reverse allostery. The conformational change differences of PARP-1 CAT regulated by allosteric inhibitors were concerned with to their interaction at the active site. Energy calculations suggested the energy advantage of EB47 in inhibiting the wild-type PARP-1, compared with D766/770A PARP-1. Secondary structure results showed the change of two key loops (αB-αD and αE-αF) in different systems. This work reported the basis of PARP-1 allostery from both thermodynamic and kinetic views, providing the guidance for the discovery and design of more innovative PARP-1 allosteric inhibitors.

Structural basis for allosteric PARP-1 retention on DNA breaks

Human PARP1 Substrates and Regulators of Its Catalytic Activity: an Updated Overview.

Clinical PARP inhibitors allosterically induce PARP2 retention on DNA

A two-step mechanism governing PARP1-DNA retention by PARP inhibitors

A PARP2-specific active site alpha-helix melts to permit DNA damage-induced enzymatic activation

A unified mechanism for PARP inhibitor-induced PARP1 chromatin retention at DNA damage sites in living cells

Unraveling the allosteric inhibition mechanism of PARP-1 CAT and the D766/770A mutation effects via Gaussian accelerated molecular dynamics and Markov state model

PARP1: Structural insights and pharmacological targets for inhibition

PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination-mediated DNA repair.

Kinetics of Poly(adp-Ribosyl)ation, but Not PARP1 Itself, Determines the Cell Fate in Response to DNA Damage in Vitro and in Vivo.

Ablation of PARP-1 does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forks

The dynamics and Regulation of PARP1 and PARP2 in response to DNA damage and during replication

Positioning loss of PARP1 activity as the central toxic event in BRCA-deficient cancer

PARP1 Binding to DNA Breaks and Hairpins Alters Nucleosome Structure

Deciphering the Functional Mechanism of Zinc Ions of PARP1 Binding with Single Strand Breaks and Double Strand Breaks.

Nucleolytic processing of abasic sites underlies PARP inhibitor hypersensitivity in ALC1-deficient BRCA mutant cancer cells

The DNA-Binding Domain of Human PARP-1 Interacts with DNA Single-Strand Breaks As a Monomer Through Its Second Zinc Finger

Modulatory Potential of Poly (ADP‐Ribose) Polymerase 1 (PARP1) in BRCA‐Mutated Tumors

Review of Poly (ADP-ribose) Polymerase (PARP) Mechanisms of Action and Rationale for Targeting in Cancer and Other Diseases

Molecular Pathways: Targeting PARP in Cancer Treatment

DNA polymerase α-primase facilitates PARP inhibitor-induced fork acceleration and protects BRCA1-deficient cells against ssDNA gaps